Table 3.
Detailed epilepsy characteristics for the patients with epilepsy
| Characteristics | IDHwt hLGG n = 50 |
IDHwt glioblastoma n = 129 |
Total epilepsy cohort n = 179 |
P-Value |
|---|---|---|---|---|
| Seizure days patients with epilepsy before diagnosis, median (IQR) | 4.0 (1.0–8.5) | 1.0 (1.0–2.0) | 2.0 (1.0–5.0) | <.001 |
| Seizure days patients with epilepsy after diagnosis, median (IQR) | 2.0 (1.0–7.5) | 3.0 (1.0–5.8) | 3.0 (1.0–5.5) | .708 |
| Seizure days, total, median (IQR) | 7.0 (2.8–20.0) | 3.0 (1.0–7.0) | 4.0 (2.0–10.0) | .005 |
| Seizure days within 3 months before last follow-up, median (IQR) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | .851 |
| Motor seizures*a | .081 | |||
| Motor, no. (%) | 31 (62%) | 77 (60%) | 108 (60%) | |
| Nonmotor, no. (%) | 17 (34%) | 32 (25%) | 49 (27%) | |
| Unknown, no. (%) | 2 (4%) | 20 (16%) | 22 (12%) | |
| Impaired awarenessa | .191 | |||
| Aware, no. (%) | 18 (37%) | 49 (38%) | 67 (37%) | |
| Impaired, no.(%) | 30 (60%) | 64 (50%) | 94 (53%) | |
| Unknown, no. (%) | 2 (4%) | 16 (12%) | 18 (10%) | |
| Bilateral tonic-clonic seizuresa | .085 | |||
| Yes, no. (%) | 23 (46%) | 45 (35%) | 68 (38%) | |
| No, no. (%) | 26 (52%) | 69 (54%) | 95 (53%) | |
| Unknown, no. (%) | 1 (2%) | 15 (12%) | 16 (9%) |
Abbreviations: IDHwt hLGG, IDHwt glioma WHO grade 2 and 3 with molecular glioblastoma-like profile; IQR, interquartile range; no., number of patients.
aDominant seizure type was used in patients who experienced different types during the course of disease.